GlassScriptPhysician profile
Bhagwat P Patel
NPI 1225060064
$2,069.91
in general payments reported to CMS, 2019-2025
29 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $309 · 2021: $256 · 2022: $393 · 2023: $537 · 2024: $237 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $920.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $395.28 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $325.94 | 2019-2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $182.43 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $179.24 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.23 | 2019-2025 | Jardiance |
| Dexcom, INC. | $110.08 | 2022-2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $97.34 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $67.12 | 2021-2023 | Verquvo, Belsomra, Steglujan |
| Mannkind Corporation | $59.40 | 2022 | |
| Lilly USA, LLC | $57.71 | 2022-2023 | Mounjaro |
| Amgen INC. | $55.49 | 2019-2025 | Repatha, Otezla, Otezla |
| Amarin Pharma, INC. | $46.96 | 2020 | |
| Astellas Pharma US INC | $43.20 | 2021-2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $29.75 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $26.51 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $24.04 | 2020 | |
| Eisai INC. | $22.21 | 2021 | |
| Hologic Sales and Service, LLC | $21.07 | 2023 | Thinprep 2000 Processor, Aptima |
| Azurity Pharmaceuticals, INC. | $19.59 | 2024 | Edarbi |
| Bayer Healthcare Pharmaceuticals INC. | $18.23 | 2021 | |
| Embecta Corp. | $18.22 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Abbvie INC. | $17.20 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.62 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.92 | 2021 | |
| Esperion Therapeutics, INC. | $13.82 | 2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.33 | 2019 | |
| Biogen, INC. | $13.22 | 2024 | Skyclarys |
| Teva Pharmaceuticals USA, INC. | $12.53 | 2019 | |
| Promius Pharma LLC | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhagwat Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.